Target Price | $2.00 |
Price | $1.02 |
Potential |
96.08%
register free of charge
|
Number of Estimates | 1 |
1 Analyst has issued a IRIDEX Corporation price target 2026.
The average IRIDEX Corporation target price is $2.00.
This is
96.08%
register free of charge
|
|
A rating was issued by 1 analysts: 0 Analysts recommend IRIDEX Corporation to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the IRIDEX Corporation stock has an average upside potential 2026 of
96.08%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 48.67 | 52.00 |
6.17% | 6.84% | |
EBITDA Margin | -15.86% | -4.81% |
7.66% | 65.97% |
1 Analyst has issued a sales forecast IRIDEX Corporation 2025 . The average IRIDEX Corporation sales estimate is
This results in the following potential growth metrics:
2024 | $48.7m | 6.17% |
---|---|---|
2025 |
$52.0m
6.84%
Unlock
|
1 Analyst has issued an EBITDA forecast IRIDEX Corporation 2025 . The average IRIDEX Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $-7.7m | 13.36% |
---|---|---|
2025 |
$-2.5m
63.66%
Unlock
|
2024 | -15.86% | 7.66% |
---|---|---|
2025 |
-4.81%
65.97%
Unlock
|
Dec '24 |
2025 Estimates |
|
---|---|---|
EV/Sales | 0.47 |
Based on analysts' sales estimates for 2025, the IRIDEX Corporation stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
Current | 0.43 | 46.91% |
---|---|---|
2025 |
0.47
10.16%
Unlock
|
Current | 0.35 | 59.49% |
---|---|---|
2025 |
0.51
45.01%
Unlock
|
IRIDEX Corporation...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.